ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR).
Authors: Earl, H.M., Hickish, T. et al.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Volume: 32
Issue: 15
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/jco.2014.32.15_suppl.1014
Source: Web of Science (Lite)
ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR).
Authors: Hickish, Hickish, T. et al.
Conference: NCRI Cancer Conference in the Clinical Trials Showcase
Dates: 2-5 November 2014
Source: Manual
Preferred by: Tamas Hickish